58.50
-0.60
(-1.02%)
At close: 12:15:45 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,538,352.00
1,538,352.00
1,866,166.00
1,827,176.00
1,811,757.00
Cost of Revenue
774,075.00
774,075.00
827,291.00
804,957.00
886,250.00
Gross Profit
764,277.00
764,277.00
1,038,875.00
1,022,219.00
925,507.00
Operating Expense
589,697.00
589,697.00
652,562.00
605,356.00
655,927.00
Operating Income
174,580.00
174,580.00
386,313.00
416,863.00
269,580.00
Net Non Operating Interest Income Expense
-611.00
-611.00
-2,991.00
-3,914.00
-4,387.00
Pretax Income
188,423.00
188,423.00
365,057.00
395,764.00
336,551.00
Tax Provision
35,396.00
35,396.00
76,057.00
91,189.00
51,870.00
Net Income Common Stockholders
162,910.00
162,910.00
281,258.00
304,575.00
301,402.00
Diluted NI Available to Com Stockholders
162,910.00
162,910.00
281,258.00
304,575.00
301,402.00
Basic EPS
7.88
--
13.59
14.60
14.34
Diluted EPS
7.88
--
13.56
14.57
14.31
Basic Average Shares
20,635.25
--
20,702.55
20,861.30
21,035.32
Diluted Average Shares
20,656.30
--
20,730.85
20,861.30
21,058.56
Total Expenses
1,363,772.00
1,363,772.00
1,479,853.00
1,410,313.00
1,542,177.00
Net Income from Continuing & Discontinued Operation
162,910.00
162,910.00
281,258.00
304,575.00
301,402.00
Normalized Income
153,864.32
153,864.32
288,525.01
303,199.75
302,962.64
Interest Income
6,431.00
6,431.00
2,221.00
537.00
390.00
Interest Expense
7,042.00
7,042.00
5,212.00
4,451.00
4,777.00
Net Interest Income
-611.00
-611.00
-2,991.00
-3,914.00
-4,387.00
EBIT
195,465.00
195,465.00
370,269.00
400,215.00
341,328.00
EBITDA
389,492.00
389,492.00
553,845.00
582,879.00
520,740.00
Reconciled Cost of Revenue
774,075.00
774,075.00
827,291.00
804,957.00
886,250.00
Reconciled Depreciation
194,027.00
194,027.00
183,576.00
182,664.00
179,412.00
Net Income from Continuing Operation Net Minority Interest
153,027.00
153,027.00
289,000.00
304,575.00
301,402.00
Total Unusual Items Excluding Goodwill
-1,031.00
-1,031.00
600.00
1,787.00
-1,845.00
Total Unusual Items
-1,031.00
-1,031.00
600.00
1,787.00
-1,845.00
Normalized EBITDA
390,523.00
390,523.00
553,245.00
581,092.00
522,585.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-193.68
-193.68
125.01
411.75
-284.36
12/31/2020 - 10/15/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
6935.TWO Prince Pharmaceutical Co., Ltd.
24.10
-0.41%
6467.TWO TAHO Pharma
48.80
-2.79%
6483.TWO Original BioMedicals Co., Ltd.
10.75
-2.27%
4117.TWO General Biologicals Corporation
18.50
-3.14%
6621.TWO UniPharma Co., Ltd.
14.15
+0.35%
4166.TWO Orient Pharma Co., Ltd.
38.35
-3.03%
1780.TWO Allied Biotech Corporation
17.10
+0.29%
6817.TWO Winston Medical Supply Co., Ltd.
90.90
-1.73%
4172.TWO InnoPharmax Inc.
16.20
-1.22%
6677.TWO Anxo Pharmaceutical Co., Ltd.
25.50
+0.20%